Summary
A phase II trial of gemcitabine (difluorodeoxycytidine) was conducted in 14 patients with advanced colorectal adenocarcinoma. Gemcitabine was administered intravenously over 30 minutes at weekly intervals for 3 consecutive weeks each month. The starting dose was 800 mg/m2, with dose escalation as tolerated. No complete or partial response were observed. Ten patients experienced progressive disease while on therapy. Toxic effects were primarily hematologic in nature. Grade 3 toxicities included leukopenia (one patient at 1000 mg/m2), granulocytopenia (two patients at 800 mg/m2), anemia (two patients at 800 mg/m2), and myalgia (one patient at 800 mg/m2). No grade 4 toxic effects or treatment-associated deaths were observed. Gemcitabine, at the doses and schedule used in this study, did not demonstrate activity against advanced colorectal adenocarcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Heidelberg C, Chandhari NK, Danneberg P, (et al.): Fluorinated pyrmidine: a new class of tumor-inhibiting compounds. Nature 179:663–666, 1957
Abbruzzese JL, Levin B: Treatment of advanced colorectal cancer. New Perspectives in Large Bowel Cancer. The Hematology/Oncology Clinics of North America 3:135–153, 1989
Ehrlichman C, Fine S, Wong A (et al.): A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469–475, 1988
Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, Mayer RJ, Schinella R, Green MD, Muggia FM: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7:1419–1426, 1989
Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Krook JE, Mailliard JA, Laurie JA, Tschetter LK: Biochemical modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7:1419–1426, 1989
O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin, S, Comis RL: Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 8:1497–1503, 1990
Pazdur R, Anjani JA, Patt YZ, Winn R, Jackson D, Sheperd B, DuBrow R, Campos L, Quaraishi M, Faintuch J, Abbruzzese JL, Gutterman J, Levin B: Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8:2027–2031, 1990
Wadler S, Lembersky B, Atkins M, Kirkwood J, Petrelli N: Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 9:1806–1810, 1991
Einhorn LH: Improvements in fluorouracil chemotherapy? J Clin Oncol 7:1377–1379, 1989
Hertel LW, Kroin JS, Misner JW, (et al): Synthesis of 2-deoxy-2′, 2′-difluoro-D-ribose and 2-deoxy-2′, 2′-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53: 2406–2409, 1988
Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytine). Cancer Res 50:4417–4422, 1990
Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarasshoff P, Plunkett W: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498, 1991
Miller AB, Hoogstraten B, Staquet M (et al): Reporting results of cancer treatment. Cancer 47:207–214, 1981
Ajani JA, Abbruzzese JL, Goudeau P, Faintuch J, Yeomans A, Boman B, Levin B: Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 6:1703–1707, 1988
Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodexoycytidine and 1-(beta)-D-arabinofuranosylcytosine. Cancer Res 48:4024–4031, 1988
Anderson H, Lund B, Hanse HH, (et al): Phase II study of gemcitabine in non-small cell lung cancer (Abstract). Proc American Society Clinical Oncology 10: 247, 1991
Casper ES, Green MR, Brown TD, (et al.): Phase II trial of Gemcitabine (2′,2′-difluorodeoxycytidine) in patients with pancreatic cancer (Abstract). Proc American Society Clinical Oncology 10:143, 1991
Grunewald R, Abbruzzese JL, Tarasoff P, Plunkett W: Saturation of 2′,2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27: 258–262, 1991
Grunewald R, Kantarjian H, Keating MJ, (et al): Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823–6826, 1990
Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W: Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406–413, 1992
Raber M, Abbruzzese JL, Lippman S, Fossella F, Gravel D, Plunkett W, Tarassoff P: Phase I/II studies of escalated doses of gemcitabine in patients with solid tumors. 7th EORTC/NCI: Symposium on New Drugs in Cancer Therapy, Amsterdam, The Netherlands Annals of Oncology 3:135, 1992 (Supplement 1)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moore, D.F., Pazdur, R., Daugherty, K. et al. Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs 10, 323–325 (1992). https://doi.org/10.1007/BF00944189
Issue Date:
DOI: https://doi.org/10.1007/BF00944189